.... 2023 Crohn’s disease Perianal Fistula Abdominal surgery Tobacco Anti-Tumor necrosis factor Infliximab Adalimumab Vedolizumab Ustekinumab Inflammatory bowel disease (IBD) is a lifelong disease characterized by chronic inflammation of the gastrointestinal tract. It is divided...

...Manuel Sutter; Petr Hruz; Jan Hendrik Niess Background: TNF inhibitors are relatively safe drugs, but asymptomatic infliximab-induced high serum creatine kinase (CK) levels have been reported in >30% of patients with inflammatory bowel disease (IBD). Whether high serum CK levels are a specific...

... patients have been suffering from the life-long disease burden; however, the emergence of biologics, namely, the first anti-TNF agent infliximab (IFX), has dramatically changed the clinical course of patients with CD [2]. Anti-TNF agents have been shown to be effective in inducing and maintaining remission...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Inflammatory bowel disease Primary failure Infliximab Adalimumab...

...Niels Teich; Michael Bläker; Frank Holtkamp-Endemann; Eric Jörgensen; Andreas Stallmach; Susanne Hohenberger Introduction: Infliximab (IFX) therapy is efficacious for inducing and maintaining symptomatic remission in patients with Crohn’s disease (CD), but whether this benefit results in reduced...

... consequences in patient care. Methods: We retrospectively collected clinical data of 104 IBD patients treated with infliximab or adalimumab in our IBD clinic. Patients with TL and ADA measurements between June 2015 and February 2018 were included. Results: The main reason for determining TL was increased...

... patients had diarrhea, 64% had abdominal pain, 42% had bloody stool, 27% had emesis, and 18% developed fever. In total, 33% were successfully treated with corticosteroids alone; 66% were steroid-refractory and treated with infliximab or vedolizumab. Two of these patients developed severe complications...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Crohn’s disease Infliximab Expert opinion Primary nonresponder...

...Tanay Kaymak; Federico Moriconi; Jan H. Niess; Christoph Beglinger; Petr Hruz Background: Many patients with moderate to severe Crohn’s disease (CD) are treated with infliximab (IFX). As most of these patients experience a long-lasting therapy, the outcome and withdrawal of IFX treatment...